Effect of Dilazep Dihydrochloride on Plasma P-Selectin Concentrations in Patients with IgA Nephropathy

Ebihara, Isao; Nakamura, Tsukasa; Suzuki, Shingo; Ushiyama, Chifuyu; Shimada, Noriaki; Suzaki, Masataka; Koide, Hikaru

doi:10.1159/000045675

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numabe et al [23] reported that treatment with dilazep through vascular and nonvascular effects maintains brain function in animals susceptible to vascular injury and organ dysfunction. Dilazep dihydrochloride is commonly used in patients with IgA nephropathy, ischaemic heart disease, polycystic kidney disease or diabetic nephropathy [8,21,24,25], and it is known to cause an increase in cerebral blood flow [6]. Dilazep dihydrochloride is reported to show the suppression of platelet adhesion and coagulation, the suppression of the platelet phospholipase activity, and maintenance of glomerular filtration rate due to increased renal blood flow [8].…”

Section: Discussionmentioning

confidence: 99%

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Nakamura

Kawagoe

Matsuda

et al. 2004

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Nakamura

Kawagoe

Matsuda

et al. 2004

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dilazep is also known to have a vasodilating effect on coronary, cerebral and renal vessels and is often used in patients with ischemic heart disease, cerebral ischemia, or renal dysfunction to improve blood irrigation of tissue [7][8][9]. The indications for registered use of dilazep dihydrochloride in Japan are indolent ischemic heart diseases and angina pectoris and reduction of urinary protein in IgA nephropathy.…”

Section: Introductionmentioning

confidence: 99%

Effect of Dilazep Dihydrochloride on Serum Cardiac Troponin T Levels in Hemodialysis Patients

Nakamura

Ushiyama

Osada

et al. 2002

Kidney Blood Press Res

Self Cite

View full text Add to dashboard Cite

Background/Aim: Cardiac troponin T is a highly sensitive marker for the detection of myocardial injury. We studied whether dilazep dihydrochloride affects cardiac troponin T levels in hemodialysis patients. Methods: Our study included 60 hemodialysis patients without symptoms of acute myocardial ischemia. We measured serum cardiac troponin T levels by the Elecsys^® troponin T assay and randomized 40 hemodialysis patients with left ventricular hypertrophy (LVH) into two treatment groups: a dilazep dihydrochloride group (300 mg/day, n = 20) and a placebo group (n = 20). Treatment was continued for 12 months. Results:There were no significant differences between pre- and postdialysis cardiac troponin T levels before treatment. LVH was noted in 40 patients out of 60 hemodialysis patients (67%). Cardiac troponin T levels were significantly higher in these patients (0.23 ± 0.08 µg/l) than in hemodialysis patients without LVH (0.09 ± 0.03 µg/l). Cardiac troponin T levels were reduced from 0.24 ± 0.08 to 0.12 ± 0.06 µg/l (p < 0.01) in patients treated with dilazep dihydrochloride. There were no change in cardiac troponin T levels in patients receiving placebo (from 0.21 ± 0.08 at baseline to 0.20 ± 0.07 µg/l). Conclusion: Dilazep dihydrochloride may be effective in ameliorating myocardial damage in hemodialysis patients.

show abstract

“…In the study, the P-selectin expression level in plasma and urine in patients with IgA nephropathy was detected, and the relationship between the patients’ histology and urinary protein excretion was analyzed. Therefore, plasma P-selectin is a helpful biomarker for the activity of IgA nephropathy, and dilazep dihydrochloride is an efficacious drug for reducing plasma soluble P-selectin levels in patients with IgA nephropathy ( 91 ). Interestingly and coincidentally, P-selectin, also named SELP, as a marker representing disease activity, cellular activation, and inflammatory mediators, is one of three selected biomarkers related to DN in our study.…”

Section: Discussionmentioning

confidence: 99%

Identification of a novel immune landscape signature as effective diagnostic markers related to immune cell infiltration in diabetic nephropathy

Zhou

Lin²,

Yang³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe study aimed to identify core biomarkers related to diagnosis and immune microenvironment regulation and explore the immune molecular mechanism of diabetic nephropathy (DN) through bioinformatics analysis.MethodsGSE30529, GSE99325, and GSE104954 were merged with removing batch effects, and different expression genes (DEGs) were screened at a criterion |log2FC| >0.5 and adjusted P <0.05. KEGG, GO, and GSEA analyses were performed. Hub genes were screened by conducting PPI networks and calculating node genes using five algorithms with CytoHubba, followed by LASSO and ROC analysis to accurately identify diagnostic biomarkers. In addition, two different GEO datasets, GSE175759 and GSE47184, and an experiment cohort with 30 controls and 40 DN patients detected by IHC, were used to validate the biomarkers. Moreover, ssGSEA was performed to analyze the immune microenvironment in DN. Wilcoxon test and LASSO regression were used to determine the core immune signatures. The correlation between biomarkers and crucial immune signatures was calculated by Spearman analysis. Finally, cMap was used to explore potential drugs treating renal tubule injury in DN patients.ResultsA total of 509 DEGs, including 338 upregulated and 171 downregulated genes, were screened out. “chemokine signaling pathway” and “cell adhesion molecules” were enriched in both GSEA and KEGG analysis. CCR2, CX3CR1, and SELP, especially for the combination model of the three genes, were identified as core biomarkers with high diagnostic capabilities with striking AUC, sensitivity, and specificity in both merged and validated datasets and IHC validation. Immune infiltration analysis showed a notable infiltration advantage for APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. In addition, the correlation analysis showed that CCR2, CX3CR1, and SELP were strongly and positively correlated with checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. Finally, dilazep was screened out as an underlying compound for DN analyzed by CMap.ConclusionsCCR2, CX3CR1, and SELP are underlying diagnostic biomarkers for DN, especially in their combination. APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation may participate in the occurrence and development of DN. At last, dilazep may be a promising drug for treating DN.

show abstract

Effect of Dilazep Dihydrochloride on Plasma P-Selectin Concentrations in Patients with IgA Nephropathy

Cited by 3 publications

References 8 publications

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Effect of Dilazep Dihydrochloride on Serum Cardiac Troponin T Levels in Hemodialysis Patients

Identification of a novel immune landscape signature as effective diagnostic markers related to immune cell infiltration in diabetic nephropathy

Contact Info

Product

Resources

About